Loading
Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.
Aleksandar Sekulic is a dermatologist and physician-scientist at Mayo Clinic in Arizona. He was first author of the 2012 New England Journal of Medicine report of ERIVANCE BCC, the phase 2 trial in which the Hedgehog pathway inhibitor vismodegib produced responses in most patients with locally advanced and in a third of those with metastatic basal cell carcinoma, the basis of the drug's approval.
| Title | Journal | Year |
|---|---|---|
| ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma | New England Journal of Medicine | 2012 |
Shares Locally advanced and metastatic basal cell carcinoma, Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Locally advanced and metastatic basal cell carcinoma, Skin cancer (all types) and the tag skin.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares the tags targeted-therapy, trialist.